<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nkgen Biotech, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock</link>
<description>Latest news and press releases for Nkgen Biotech, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 12:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nkgen-biotech-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-to-present-troculeucel-mechanism-data-in-alzheimers-and-frontotemporal-dementia-at-the-neuroimmunology-drug-development-summit</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-to-present-troculeucel-mechanism-data-in-alzheimers-and-frontotemporal-dementia-at-the-neuroimmunology-drug-development-summit</guid>
<pubDate>Thu, 09 Apr 2026 12:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts. NKGen’s Cha</description>
</item>
<item>
<title>NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-cognitive-improvements-and-biomarker-correlations-in-alzheimers-disease-at-adpd-2026tm</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-cognitive-improvements-and-biomarker-correlations-in-alzheimers-disease-at-adpd-2026tm</guid>
<pubDate>Mon, 23 Mar 2026 12:05:00 GMT</pubDate>
<description>Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function. Exploratory plasma GFAP correlations are consistent with observed clinical outcomes. Findings support further evaluation of troculeucel’s immunomodulatory approach in the ongoing Phase 2 trial. SANTA ANA, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN</description>
</item>
<item>
<title>NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-names-leading-dementia-130500354</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-names-leading-dementia-130500354</guid>
<pubDate>Thu, 22 Jan 2026 13:05:00 GMT</pubDate>
<description>Dr. Miller’s appointment further enhances NKGen’s scientific and clinical advisory capabilities as the Company advances its research in Alzheimer’s and other related neurodegenerative diseasesSANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the appoin</description>
</item>
<item>
<title>NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-inc-issues-statement-130500817</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-inc-issues-statement-130500817</guid>
<pubDate>Wed, 03 Dec 2025 13:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. (“NKGen Korea”), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the “NKGen Korea Board”). NKGen Korea, former</description>
</item>
<item>
<title>NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-provides-clarification-quotation-120500480</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-provides-clarification-quotation-120500480</guid>
<pubDate>Thu, 09 Oct 2025 12:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today issued the following statement in response to recent shareholder inquiries regarding its current trading status on the OTC Expert Market and the display of a $0.00 common stock, $0.0001 par value per share (the “</description>
</item>
<item>
<title>NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-neurodegenerative-120500103</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-neurodegenerative-120500103</guid>
<pubDate>Mon, 06 Oct 2025 12:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the XXVII World Congress of Neurology (“WCN 2025”) taking place in Seoul, South Korea, October 12-15, 2025. WCN 20</description>
</item>
<item>
<title>NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-neurodegenerative-120500013</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-neurodegenerative-120500013</guid>
<pubDate>Thu, 18 Sep 2025 12:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 3rd China Great Bay Cell and Gene Therapy Forum, taking place in Guangzhou, China, September 25-26, 2025. Dr.</description>
</item>
<item>
<title>NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-inc-announces-completion-120500863</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-inc-announces-completion-120500863</guid>
<pubDate>Tue, 09 Sep 2025 12:05:00 GMT</pubDate>
<description>NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026.Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song. SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biote</description>
</item>
<item>
<title>NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-allogeneic-enhanced-120000294</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-allogeneic-enhanced-120000294</guid>
<pubDate>Wed, 06 Aug 2025 12:00:00 GMT</pubDate>
<description>SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 13th Annual Immuno-Oncology Summit (the “Summit”) to be held in Philadelphia, PA, from August 11 - 13, 2025. T</description>
</item>
<item>
<title>NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-presents-troculeucel-mechanism-120500906</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-presents-troculeucel-mechanism-120500906</guid>
<pubDate>Mon, 28 Jul 2025 12:05:00 GMT</pubDate>
<description>Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was shown to internalize and digest amyloid and α-synuclein proteins in vitro and to improve CSF levels of amyloid, α-synuclein, and p-tau in Phase 1 patients in a largely dose-dependent manner. Troculeucel identifies and eliminates auto-activated T cells without disrupting resting T ce</description>
</item>
<item>
<title>NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-alzheimer-association-120500306</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-alzheimer-association-120500306</guid>
<pubDate>Tue, 22 Jul 2025 12:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Associ</description>
</item>
<item>
<title>NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-receives-fda-expanded-access-120000161</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-receives-fda-expanded-access-120000161</guid>
<pubDate>Mon, 21 Jul 2025 12:00:00 GMT</pubDate>
<description>Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer’s Disease.Company receives expanded access protocol authorization from the U.S. Food and Drug Administration (FDA) for troculeucel granted to treat patients with known diagnoses of multiple neurodegenerative diseases. IND approval allows for up to 20 patients to be enrolled; first patient e</description>
</item>
<item>
<title>NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-hekabio-enter-strategic-200500995</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-hekabio-enter-strategic-200500995</guid>
<pubDate>Thu, 17 Jul 2025 20:05:00 GMT</pubDate>
<description>In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell therapy, troculeucel, in Japan. Under Japan’s Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class forerunner for the treatment of several intractable neurodegenerativ</description>
</item>
<item>
<title>NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-announces-funding-regain-214500711</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-announces-funding-regain-214500711</guid>
<pubDate>Wed, 16 Jul 2025 21:45:00 GMT</pubDate>
<description>Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting obligations and listing standards. Share trading will move to the OTC Expert Market temporarily, with potential to uplist to OTCQB as soon as SEC filings are current, with plan to return to Nasdaq or to NYSE American. SANTA ANA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“</description>
</item>
<item>
<title>Delisting of Securities from The Nasdaq Stock Market</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/delisting-of-securities-from-the-nasdaq-stock-market</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/delisting-of-securities-from-the-nasdaq-stock-market</guid>
<pubDate>Fri, 11 Jul 2025 20:05:00 GMT</pubDate>
<description>NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of NKGen Biotech, Inc. NKGen Biotech, Inc.’s securities were suspended on March 5, 2025 and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock, rights, and units of Aquaron Acquisition Corp. Aquaron Acquisition Corp.’s securities were suspended on March 7, 2025 and have not traded on Nasdaq since that time.</description>
</item>
<item>
<title>NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-administers-first-dose-203000889</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-administers-first-dose-203000889</guid>
<pubDate>Thu, 10 Jul 2025 20:30:00 GMT</pubDate>
<description>SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and</description>
</item>
<item>
<title>NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-announces-international-u-120500448</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-announces-international-u-120500448</guid>
<pubDate>Mon, 23 Jun 2025 12:05:00 GMT</pubDate>
<description>SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of two additional clinical trial sites for its ongoing Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s di</description>
</item>
<item>
<title>NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-chairman-ceo-paul-120500347</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-chairman-ceo-paul-120500347</guid>
<pubDate>Thu, 08 May 2025 12:05:00 GMT</pubDate>
<description>New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) c</description>
</item>
<item>
<title>NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-clinical-120000527</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-clinical-120000527</guid>
<pubDate>Wed, 07 May 2025 12:00:00 GMT</pubDate>
<description>SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company’s Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s dise</description>
</item>
<item>
<title>NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition</title>
<link>https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-alzheimer-120000318</link>
<guid isPermaLink="true">https://6ix.com/company/nkgen-biotech-inc-common-stock/news/nkgen-biotech-present-troculeucel-alzheimer-120000318</guid>
<pubDate>Mon, 14 Apr 2025 12:00:00 GMT</pubDate>
<description>SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, C</description>
</item>
</channel>
</rss>